Alto Neuroscience, Inc. (ANRO): who owns it and who trades it
As of Nov 16, 2026, ANRO insiders reported 3 open-market sales worth $3.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nicholas Conrad Smith (CFO), with $3.6M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Alto Neuroscience
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANRO
115 funds and institutions reported ANRO shares worth $780M at the end of Q2 2026, about 93% of the company. The largest holder is Alpha Wave Global, LP with 11.6%.
Funds and institutions (13F) 93%Everyone else 7%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Alpha Wave Global, LP | 3.71M | 11.61% | $97.8M | No change |
| Commodore Capital LP | 2.72M | 8.52% | $71.9M | No change |
| BlackRock, Inc. | 2.12M | 6.64% | $56M | +218% |
| Perceptive Advisors LLC | 1.61M | 5.04% | $42.5M | -20% |
| Adage Capital Partners Gp, L.l.c. | 1.60M | 5.01% | $42.2M | +316% |
| Vanguard Capital Management LLC | 1.39M | 4.35% | $36.7M | +15% |
| Spruce Street Capital LP | 1.35M | 4.24% | $35.7M | +2% |
| Vivo Capital, LLC | 1.21M | 3.78% | $31.9M | +17% |
| Franklin Resources Inc | 1.01M | 3.17% | $26.7M | -8% |
| Armistice Capital, LLC | 864,000 | 2.70% | $22.8M | -5% |
| Affinity Asset Advisors, LLC | 850,000 | 2.66% | $22.4M | +70% |
| Vestal Point Capital, LP | 785,000 | 2.46% | $20.7M | -62% |
| State Street Corp | 685,945 | 2.15% | $18.1M | +244% |
| Geode Capital Management, LLC | 678,199 | 2.12% | $17.9M | +132% |
| 72 Investment Holdings, LLC | 667,778 | 2.09% | $17.6M | No change |
| Northern Trust Corp | 632,701 | 1.98% | $16.7M | +34% |
| Millennium Management LLC | 558,320 | 1.75% | $14.7M | -32% |
| Point72 Asset Management, L.P. | 502,950 | 1.57% | $13.3M | No change |
| Venrock Adviser, LLC | 500,000 | 1.57% | $13.2M | No change |
| Integral Health Asset Management, LLC | 500,000 | 1.57% | $13.2M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANRO insiders reported $0 of open-market purchases and $3.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Nicholas Conrad Smith | CFO | Sale | 23,170 | $25.78 | $597K | Form 4 |
| Sep 30, 2026 | Nicholas Conrad Smith | CFO | Sale | 886 | $26.87 | $23.8K | Form 4 |
| Sep 29, 2026 | Nicholas Conrad Smith | CFO | Sale | 110,830 | $26.58 | $2.9M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Nicholas Conrad Smith | PRESIDENT AND CFO | – | $3.6M | Sep 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANRO short interest
High short interest. 14.5% of ANRO shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 253%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.68M ANRO shares were sold short, 14.5% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 540,536 shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.68M | 14.48% | +9% | 540,536 | 10.5 |
| Oct 15, 2026 | 5.20M | 13.26% | +12% | 694,107 | 7.5 |
| Sep 30, 2026 | 4.66M | 11.88% | +12% | 718,187 | 6.5 |
| Sep 15, 2026 | 4.17M | 10.64% | +9% | 459,493 | 9.1 |
| Aug 31, 2026 | 3.84M | 9.78% | +8% | 475,830 | 8.1 |
| Aug 14, 2026 | 3.56M | 9.06% | +10% | 475,999 | 7.5 |
| Jul 31, 2026 | 3.24M | 10.13% | +4% | 434,265 | 7.5 |
| Jul 15, 2026 | 3.10M | 9.69% | +28% | 719,885 | 4.3 |
| Jun 30, 2026 | 2.41M | 7.54% | +49% | 805,527 | 3.0 |
| Jun 15, 2026 | 1.62M | 5.08% | -4% | 373,591 | 4.3 |
| May 29, 2026 | 1.69M | 5.30% | +5% | 305,825 | 5.5 |
| May 15, 2026 | 1.61M | 5.05% | +2% | 343,534 | 4.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Alto Neuroscience company events
Alto Neuroscience filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 27, 2026LeadershipOn August 26, 2026 (the “ Effective Date” ), the Board of Directors of Alto Neuroscience, Inc. promoted Nicholas C. Smith, the Company’s Chief Financial Officer and Chief Business Officer, to the position of President and Chief Financial Officer, effective immediately. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 14, 2026AgreementAlto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, Inc., as representative of the several underwriters set forth therein, to issue and sell 3,776,436 shares of common stock of the Company, par value $0.0001 per share, in an underwritten registered direct offering… Filing
- Jul 13, 2026AnnouncementOf this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any… Filing
- May 28, 2026LeadershipAppointment of Andrew Miller, Ph.D. to the Board On May 27, 2026, the Board of Directors of Alto Neuroscience, Inc., following the recommendation of the Board’s Nominating and Corporate Governance Committee, unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board. Filing
- May 13, 2026LeadershipEquity Plan Amendments As noted in Item 5.07 below, at the Alto Neuroscience, Inc. 2026 annual meeting of stockholders, the Company’s stockholders approved the Amended and Restated 2024 Employee Stock Purchase Plan. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 1, 2026AnnouncementAlto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is… Filing
- Mar 16, 2026AgreementAlto Neuroscience, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (i) 2,900,000 shares of the Company’s common stock, par value $0.0001, and (ii) with… Filing
- Mar 16, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Alto Neuroscience financials
Famous investors that hold ANRO
2 of the 50 well-known investors we track reported holding ANRO in their latest 13F filing. The largest position is Steve Cohen's, worth $14.7M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 576,375 | $14.7M | 0.0% | +15% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 23,164 | $591K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ANRO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.0% |
Questions about Alto Neuroscience, Inc. (ANRO) stock
Who owns the most ANRO stock?
The largest reported owner of Alto Neuroscience, Inc. (ANRO) is Alpha Wave Global, LP, with 11.6% of the company. In total, 115 funds and institutions reported holding ANRO at the end of Q2 2026, together about 93% of the shares. See the largest owners.
Are ANRO insiders buying or selling?
In the last 12 months, ANRO insiders reported no open-market purchases and 3 sales worth $3.6M. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in ANRO?
As of Oct 30, 2026, 5.68M ANRO shares were sold short, 14.5% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 540,536 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold ANRO?
2 of the 50 well-known investors we track reported ANRO in their latest 13F filing, including Steve Cohen, Ken Griffin. The largest position is worth $14.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.